Subscribe To
HOWL / Werewolf Therapeutics, Inc. (HOWL) Reports Q1 Loss, Tops Revenue Estimates
![Werewolf Therapeutics, Inc. (HOWL) Reports Q1 Loss, Tops Revenue Estimates](https://cdn.snapi.dev/images/v1/4/c/biotech35-1885316.jpg)
HOWL News
![Why Is Werewolf Therapeutics (HOWL) Stock Up 20% Today? Why Is Werewolf Therapeutics (HOWL) Stock Up 20% Today?](https://cdn.snapi.dev/images/v1/x/b/biotechnology1600-2139128.png)
By InvestorPlace
November 3, 2023
Why Is Werewolf Therapeutics (HOWL) Stock Up 20% Today?
Werewolf Therapeutics (NASDAQ: HOWL ) stock is on the rise Friday after the company released preliminary data from the phase 1/1b clinical trial. This more_horizontal
![Werewolf: Q4 2023 Data Readout And Enhancement Of Validated Targets Werewolf: Q4 2023 Data Readout And Enhancement Of Validated Targets](https://cdn.snapi.dev/images/v1/n/v/image-1631651456-2038413.jpg)
By Seeking Alpha
August 25, 2023
Werewolf: Q4 2023 Data Readout And Enhancement Of Validated Targets
Preliminary safety and biomarker results from the phase 1/1b study, using WTX-124 for the treatment of patients with solid tumors, expected Q4 of 2023 more_horizontal
![Werewolf Therapeutics, Inc. (HOWL) Reports Q2 Loss, Tops Revenue Estimates Werewolf Therapeutics, Inc. (HOWL) Reports Q2 Loss, Tops Revenue Estimates](https://cdn.snapi.dev/images/v1/j/0/default30-2017396.jpg)
By Zacks Investment Research
August 10, 2023
Werewolf Therapeutics, Inc. (HOWL) Reports Q2 Loss, Tops Revenue Estimates
Werewolf Therapeutics, Inc. (HOWL) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.41. This comp more_horizontal
![Werewolf Therapeutics, Inc. (HOWL) Reports Q1 Loss, Tops Revenue Estimates Werewolf Therapeutics, Inc. (HOWL) Reports Q1 Loss, Tops Revenue Estimates](https://cdn.snapi.dev/images/v1/4/c/biotech35-1885316.jpg)
By Zacks Investment Research
May 11, 2023
Werewolf Therapeutics, Inc. (HOWL) Reports Q1 Loss, Tops Revenue Estimates
Werewolf Therapeutics, Inc. (HOWL) came out with a quarterly loss of $0.34 per share versus the Zacks Consensus Estimate of a loss of $0.49. This comp more_horizontal
![Werewolf Therapeutics, Inc. (HOWL) Reports Q4 Loss, Tops Revenue Estimates Werewolf Therapeutics, Inc. (HOWL) Reports Q4 Loss, Tops Revenue Estimates](https://cdn.snapi.dev/images/v1/7/h/biotech9-1809887.jpg)
By Zacks Investment Research
March 23, 2023
Werewolf Therapeutics, Inc. (HOWL) Reports Q4 Loss, Tops Revenue Estimates
Werewolf Therapeutics, Inc. (HOWL) delivered earnings and revenue surprises of 33.90% and 131.21%, respectively, for the quarter ended December 2022. more_horizontal
![Werewolf Therapeutics to Participate in a Fireside Chat at the Jefferies Global Healthcare Conference Werewolf Therapeutics to Participate in a Fireside Chat at the Jefferies Global Healthcare Conference](https://cdn.snapi.dev/images/v1/e/o/conf4-1405126.jpg)
By GlobeNewsWire
June 6, 2022
Werewolf Therapeutics to Participate in a Fireside Chat at the Jefferies Global Healthcare Conference
CAMBRIDGE, Mass., June 06, 2022 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative bi more_horizontal